T-VEC in Combination with Ipilmumab for Melanoma Treatment
Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma
Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma.
Clinical Pearls:
- Researchers used T-VEC, an oncolytic virus, because of previous positive data.
- T-VEC can unleash multiple antigens from the lysine tumor regardless of the tumor genotype. These antigens will then be presented to the dendritic cells, which are driven to the event from T-VEC.
- These dendritic cells teach T cells to start killing the tumor locally and hopefully throughout the body. In order to augment a response throughout the body, ipilimumab is used.
- Although ipilimumab helps 25% of patients live longer and have long durable responses, sometimes these responses are slow. Adding T-VEC may help speed up the responses in a safe manner.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
